Are biomarkers helpful in early diagnosis of acute kidney injury?

doi:10.3877/cma.j.issn.2096-1537.2017.01.009

Abstract

Abstract:

Acute kidney injury (AKI) is a common clinical condition which induces increased morbidity and mortality. Timely diagnosis and appropriate therapy of AKI can improve outcome. Current diagnosis of AKI is still based on the presence of oliguria and a gradual increase of serum creatinine (Scr) concentration which can not reflect the condition of AKI early. Several novel biomarkers could potentially be useful to predict AKI early in the clinical setting. In this review, we discuss about the clinical evidence of currently available biomarkers in early diagnosis of AKI.

Key words: Acute kidney injury, Biological markers, Early diagnosis

Pengfei Pan, Xiangyou Yu. Are biomarkers helpful in early diagnosis of acute kidney injury?[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2017, 03(01): 40-45.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://icu.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-1537.2017.01.009

https://icu.cma-cmc.com.cn/EN/Y2017/V03/I01/40

References 41

[1]	Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey[J]. Lancet, 2015, 386(10002): 1465–1471.
[2]	Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study[J]. Intensive Care Med, 2015, 41(8): 1411–1423.
[3]	Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group[J]. Crit Care, 2004, 8(4): R204–R212.
[4]	Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury[J]. Crit Care, 2007, 11(2): R31.
[5]	Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury[J]. Kidney Int Suppl, 2012, 2(1): 1–138.
[6]	Ostermann M, Joannidis M. Acute kidney injury 2016: diagnosis and diagnostic workup[J]. Crit Care, 2016, 20(1): 299.
[7]	De Rosa S, Samoni S, Ronco C. Creatinine-based definitions: from baseline creatinine to serum creatinine adjustment in intensive care[J]. Crit Care, 2016, 20(1): 69.
[8]	Moore E, Tobin A, Reid D, et al. The impact of fluid balance on the detection, classification and outcome of acute kidney injury after cardiac surgery[J]. J Cardiothorac Vasc Anesth, 2015, 29(5): 1229–1235.
[9]	Lehner GF, Forni LG, Joannidis M. Oliguria and biomarkers of acute kidney injury: star struck lovers or strangers in the night?[J]. Nephron, 2016, 134(3): 183–190.
[10]	Md Ralib A, Pickering JW, Shaw GM, et al. The urine output definition of acute kidney injury is too liberal[J]. Crit Care, 2013, 17(3): R112.
[11]	Ostermann M. Diagnosis of acute kidney injury: Kidney Disease Improving Global Outcomes criteria and beyond [J]. Curr Opin Crit Care, 2014, 20(6): 581–587.
[12]	Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy[J]. Nephrol Dial Transplant, 2012, 27(12): 4263–4272.
[13]	Lameire N, Vanmassenhove J, Van Biesen W, et al. The cell cycle biomarkers: promising research, but do not oversell them[J]. Clin Kidney J, 2016, 9(3): 353–358.
[14]	Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury biomarkers[J]. Nephrol Dial Transplant, 2014, 29(7): 1301–1311.
[15]	Zhou F, Luo Q, Wang L, et al. Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis[J]. Eur J Cardiothorac Surg, 2016, 49(3): 746–755.
[16]	Zhang A, Cai Y, Wang PF, et al. Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis[J]. Crit Care, 2016, 20: 41.
[17]	Sen S, Godwin ZR, Palmieri T, et al. Whole blood neutrophil gelatinase-associated lipocalin predicts acute kidney injury in burn patients[J]. J Surg Res, 2015, 196(2): 382–387.
[18]	Quintavalle C, Anselmi CV, De Micco F, et al. Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury[J]. Circ Cardiovasc Interv, 2015, 8(9): e002673.
[19]	Lin X, Yuan J, Zhao Y, et al. Urine interleukin-18 in prediction of acute kidney injury: a systemic review and meta-analysis[J]. J Nephrol, 2015, 28(1): 7–16.
[20]	Nisula S, Yang R, Poukkanen M, et al. Predictive value of urine interleukin-18 in the evolution and outcome of acute kidney injury in critically ill adult patients[J]. Br J Anaesth, 2015, 114(3): 460–468.
[21]	Li W, Yu Y, He H, et al. Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention[J]. Biomed Rep, 2015, 3(4): 509–512.
[22]	Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes[J]. J Am Soc Nephrol, 2014, 25(10): 2177–2186.
[23]	Susantitaphong P, Siribamrungwong M, Doi K, et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis[J]. Am J Kidney Dis, 2013, 61(3): 430–439.
[24]	Ho J, Tangri N, Komenda P, et al. Urinary, plasma, and serum biomarkers′ utility for predicting acute kidney injury associated with cardiac surgery in adults: a meta-analysis[J]. Am J Kidney Dis, 2015, 66(6): 993–1005.
[25]	Petrovic S, Bogavac-Stanojevic N, Lakic D, et al. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery[J]. Biochem Med (Zagreb), 2015, 25(2): 262–271.
[26]	Liu L, Xie S, Liao X, et al. Netrin-1 pretreatment protects rat kidney against ischemia/reperfusion injury via suppression of oxidative stress and neuropeptide Y expression[J]. J Biochem Mol Toxicol, 2013, 27(4): 231–236.
[27]	Wohlfhrtova M, Brabcova, Zelezny F, et al. Tubular atrophy and low netrin-1 gene expression are associated with delayed kidney allograft funtion[J]. Transplantation, 2014, 97(2): 176–183.
[28]	Lombi F, Muryan A, Canzonieri R, et al. Biomarkers in acute kidney injury: evidence or paradigm?[J]. Nefrologia, 2016, 36(4): 339–346.
[29]	Jiang C, Qi C, Sun K, et al. Diagnostic value of N-acetyl-β-D-glucosaminidase for the early prediction of acute kidney injury after percutaneous nephrolithotripsy[J]. Exp Ther Med, 2013, 5(1): 197–200.
[30]	Benzer M, Alpay H, Baykan Ö, et al. Serum NGAL, cystatin C and urinary NAG measurements for early diagnosis of contrast-induced nephropathy in children [J]. Ren Fail, 2016, 38(1): 27–34.
[31]	Andreucci M, Faga T, Riccio E, et al. The potential use of biomarkers in predicting contrast-induced acute kidney injury[J]. Int J Nephrol Renovasc Dis, 2016, 9: 205–221.
[32]	Zhang Z, Lu B, Sheng X, et al. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis[J]. Am J Kidney Dis, 2011, 58(3): 356–365.
[33]	Chen S, Shi JS, Yibulayin X, et al. Cystatin C is a moderate predictor of acute kidney injury in the early stage of traumatic hemorrhagic shock[J]. Exp Ther Med, 2015, 10(1): 237–240.
[34]	Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury[J]. Crit Care, 2013, 17(1): R25.
[35]	Bihorac A, Chawla LS, Shaw AD, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication[J]. Am J Respir Crit Care Med, 2014, 189(8): 932–939.
[36]	Pilarczyk K, Edayadiyil-Dudasova M, Wendt D, et al. Urinary [TIMP-2]*·[IGFBP7] for early prediction of acute kidney injury after coronary artery bypass surgery[J]. Ann Intensive Care, 2015, 5(1): 50.
[37]	Kimmel M, Shi J, Wasser C, et al. Urinary [TIMP-2]·[IGFBP7]-novel biomarkers to predict acute kidney injury[J]. Am J Nephrol, 2016, 43(5): 375–382.
[38]	Bell M, Larsson A, Venge P, et al. Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury[J]. Dis Markers, 2015, 2015: 158658.
[39]	Aguado-Fraile E, Ramos E, Conde E, et al. A pilot study identifying a set of microRNAs as precise diagnostic biomarkers of acute kidney injury[J]. PLoS One, 2015, 10(6): e0127175.
[40]	Sun SQ, Zhang T, Ding D, et al. Circulating microRNA-188, -30a, and -30e as early biomarkers for contrast-induced acute kidney injury[J]. J Am Heart Assoc, 2016, 5(8): e004138.
[41]	Liu X, Guan Y, Xu S, et al. Early predictors of acute kidney injury: a narrative review[J]. Kidney Blood Press Res, 2016, 41(5): 680–700.

Please choose a citation manager

Content to export